MLYS
Price:
$14.95
Market Cap:
$743.41M
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.[Read more]
Industry
Biotechnology
IPO Date
2023-02-10
Stock Exchange
NASDAQ
Ticker
MLYS
According to Mineralys Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.42. This represents a change of 34.39% compared to the average of -4.03 of the last 4 quarters.
The mean historical PE Ratio of Mineralys Therapeutics, Inc. over the last ten years is -69.23. The current -5.42 PE Ratio has changed 682.85% with respect to the historical average. Over the past ten years (40 quarters), MLYS's PE Ratio was at its highest in in the September 2022 quarter at -0.00. The PE Ratio was at its lowest in in the December 2021 quarter at -25.42.
Average
-69.23
Median
-31.20
Minimum
-210.22
Maximum
-4.33
Discovering the peaks and valleys of Mineralys Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = -4.33
Minimum Annual Increase = -82.88%
Minimum Annual PE Ratio = -210.22
Year | PE Ratio | Change |
---|---|---|
2023 | -4.33 | -82.88% |
2022 | -25.28 | -31.87% |
2021 | -37.11 | -82.35% |
The current PE Ratio of Mineralys Therapeutics, Inc. (MLYS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-22.24
5-year avg
-69.23
10-year avg
-69.23
Mineralys Therapeutics, Inc.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mineralys Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Mineralys Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Mineralys Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Mineralys Therapeutics, Inc. (MLYS)?
What is the highest PE Ratio for Mineralys Therapeutics, Inc. (MLYS)?
What is the 3-year average PE Ratio for Mineralys Therapeutics, Inc. (MLYS)?
What is the 5-year average PE Ratio for Mineralys Therapeutics, Inc. (MLYS)?
How does the current PE Ratio for Mineralys Therapeutics, Inc. (MLYS) compare to its historical average?